4. Alexi, T., et al. (2000). Neuroprotective strategies for basal ganglia degeneration: Par- 28.
kinson's and Huntington's disease. Prog. Neurobiol. 60: 409 – 470.
5. Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Schwartz, K. J., and Martin, J. B. 29.
(1986). Replication of the neurochemical characteristics of Huntington's disease by
quinolinic acid. Nature 321: 168 – 171.
6. Ferrer, I., Goutan, E., Marin, C., Rey, M. J., and Ribalta, T. (2000). Brain-derived neuro- 30.
trophic factor in Huntington's disease. Brain Res. 866: 257 – 261.
7. Marco, S., Canudas, A. M., Canals, J. M., Gavalda, N., Perez-Navaro, E., and Albech, J.
(2002). Excitatory amino acids differentially regulate the expression of GDNF, neurturin
and their receptors in the adult rat striatum. Exp. Neurol. 174: 243 – 252. 31.
8. Bresjanac, M., and Antauer, G. (2000). Reactive astrocytes of the quinolinic acid-le- sioned rat striatum express GFRalpha1 as well as GDNF in vivo. Exp. Neurol. 164: 53 – 59.
9. Martinez-Serrano, A., and Bjorklund, A. (1996). Protection of the neostriatum against 32.
excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells.
J. Neurosci. 16: 4604 – 4616. 33.
10. Schumacher, J. M., Short, M. P., Hyman, B. T., Breakefield, X. O., and Isacson, O. (1991).
Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. Neuroscience 45: 561 – 570. 34.
11. Frim, D. M., Short, M. P., Rosenberg, W. S., Simpson, J., Breakefield, X. O., and Isacson,
O. (1993). Local protective effects of nerve growth factor-secreting fibroblasts against
excitotoxic lesions in the rat striatum. J. Neurosurg. 78: 267 – 273. 35.
12. Emerich, D. F., Lindner, M. D., Winn, S. R., Chen, E.-Y., Frydel, B., and Kordower, J. H.
(1996). Implants of encapsulated human CNTF-producing fibroblasts prevent be- havioural deficits and striatal degeneration in a rodent model of Huntington's disease. 36.
J. Neurosci. 16: 5168 – 5181.
13. Emerich, D. F., et al. (1997). Cellular delivery of human CNTF prevents motor and 37.
cognitive dysfunction in a rodent model of Huntington's disease. Cell Transplant. 6:
249 – 266.
14. Emerich, D. F., et al. (1997). Protective effect of encapsulated cells producing neuro- 38.
trophic factor CNTF in a monkey model of Huntington's disease. Nature 386: 395 – 399.
15. Emerich, D. F., Bruhn, S., Chu, Y., and Kordower, J. H. (1998). Cellular delivery of CNTF
but not NT-4/5 prevents degeneration of striatal neurons in a rodent model of Hun- 39.
tington's disease. Cell Transplant. 7: 213 – 225.
16. de Almeida, L. P., Zala, D., Aebischer, P., and Deglon, N. (2001). Neuroprotective 40.
effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol. Dis. 8: 433 – 446. 41.
17. Anderson, K. D., Panayotatos, N., Corcoran, T. L., Lindsay, R. M., and Wiegand, S. J.
(1996). Ciliary neurotrophic factor protects striatal output neurons in an animal model 42.
of Huntington's disease. Proc. Natl. Acad. Sci. USA 93: 7346 – 7351.
18. Alexi, T., et al. (1999). The IGF-1 amino-terminal tripeptide glycine-proline-glutamine 43.
(GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of
Huntington's disease. Exp. Neurol. 159: 84 – 97. 44.
19. Hughes, P. E., Alexi, T., Williams, C. E., Clark, R. G., and Gluckman, P. D. (1999).
Administration of recombinant human activin-A has powerful neurotrophic effects on
select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. 45.
Neuroscience 92: 197 – 209.
20. Ventimiglia, R., Mather, P. E., Jones, B. E., and Lindsay, R. M. (1995). The neurotrophins
BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur. J. Neurosci. 7: 213 – 222. 46.
21. Mizuno, K., Carnahan, J., and Nawa, H. (1994). Brain-derived neurotrophic factor
promotes differentiation of striatal GABAergic neurons. Dev. Biol. 165: 243 – 256.
22. Nakao, N., Brundin, P., Funa, K., Lindvall, O., and Odin, P. (1995). Trophic and pro- 47.
tective actions of brain-derived neurotrophic factor on striatal DARPP-32-containing
neurons in vitro. Brain Res. Dev. Brain Res. 90: 92 – 101.
23. Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M. E. (1998). Huntingtin acts in
the nucleus to induce apoptosis but death does not correlate with the formation of 48.
intranuclear inclusions. Cell 95: 55 – 66.
24. Frim, D. M., et al. (1993). Effects of biologically delivered NGF, BDNF and bFGF on
striatal excitotoxic lesions. Neuroreport 4: 367 – 370. 49.
25. Araujo, D. M., and Hilt, D. C. (1997). Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioural and neurochemical deficits in a rodent model 50.
of Huntington's disease. Neuroscience 81: 1099 – 1110.
26. Perez-Navaro, E., Arenas, E., Marco, S., and Albech, J. (1999). Intrastriatal grafting of a
GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotox- 51.
icity in vivo. Eur. J. Neurosci. 11: 241 – 249.
27. Perez-Navarro, E., Arenas, E., Reiriz, J., Calvo, N., and Alberch, J. (1996). Glial cell line- 52.
derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from
excitotoxic damage. Neuroscience 75: 345 – 352.
